DongKoo Bio & Pharma Plans Transdermal Delivery LOI

DongKoo Bio & Pharma will sign a three-way letter of intent with U.S. biotech Pelamore and Link Korea to commercialize transdermal drug delivery technology in Korea, according to En.

En characterized the planned arrangement as a partnership involving next-generation drug delivery technology. The report identifies transdermal delivery as the technology focus and Korea as the commercialization market.

Three parties named in planned LOI

The planned LOI brings together DongKoo Bio & Pharma, Pelamore, and Link Korea, En reported. Pelamore is identified in the report as a U.S. biotech.

The supplied report does not provide further detail on the parties' respective roles under the LOI. It also does not identify a specific product or provide additional terms for the planned commercialization arrangement.

For pharmaceutical and biotech sales professionals, the announcement centers on a drug-delivery technology discussion involving organizations named by En across Korea and the United States.

Commercialization focus is Korea

According to En, the stated purpose of the planned three-way LOI is to commercialize transdermal drug delivery technology in Korea. En's headline describes the partnership as focused on next-generation drug delivery technology.

Transdermal drug delivery is the route of administration specifically named in the report. The supplied evidence does not include information about therapeutic areas, customers, distribution plans, or development status.

What En reported

• DongKoo Bio & Pharma will sign a three-way LOI.
• The other parties are Pelamore and Link Korea.
• Pelamore is described as a U.S. biotech.
• The technology focus is transdermal drug delivery.
• The stated commercialization market is Korea.

En reported the planned LOI as a partnership around transdermal drug delivery technology, with commercialization in Korea as its stated objective.